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Abstract
Background: Thailand has a high incidence of cholangiocarcinoma (CCA), particularly in the north and northeastern
regions. Most CCA patients come at a late, unresectable stage and presently no optimal screening test for CCA has
been established. We determined the prevalence of CCA in a remote northern village and explored if screening could
lead to early detection and survival benefits.
Methods: A 5-year population-based study was started in October, 2011 for consented Thai individuals, aged 30–60
years. The screening program comprised blood testing, stool examination and serial ultrasonography every 6 months.
Results: During the first 3 years, 4,225 eligible individuals were enrolled. CCA was detected in 32 patients, with a mean
age of 51.9 years (41–62 years), and 21/32 cases were at a curative resectable stage. The prevalence rate of CCA was
165.7 per 100,000 and one- and two-year incidence rate was 236.7/100,000 and 520.7/100,000, respectively. One- and
2-year overall survival rates of CCA patients were 90.9 and 61.5 %, respectively. Prognosis was better in resectable cases
with 100 % 1-year and 77.8 % 2-year survival rates. Interestingly, premalignant pathological lesions (stage 0) were
identified in 11 cases with 100 % 3-year survival rate. Serum biomarkers and alkaline phosphatase were not sufficient to
detect early-stage disease. In 22 patients, stool samples were positive for Opisthorchis viverrini, based on polymerase
chain reaction.
Conclusion: Detection of premalignant lesions and early-stage resectable CCA by ultrasonography resulted in
improved clinical outcome. Ultrasonography should be offered as a first screening tool for CCA in an endemic area
until other useful biological markers become available.
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Background
Cholangiocarcinoma is a tumor of the biliary tract, pre-
sumably of cholangiocytic origin, with a rising global in-
cidence [1–6]. Several known risk factors exist, linking
chronic biliary inflammation to the pathogenesis of chol-
angiocarcinoma [7, 8]. Late presentation to hospital,
with a median survival of months, is noted in most pa-
tients in developing countries whereby cholangiocarci-
noma is most prevalent. Moreover, the pathological or
cytological diagnosis of cholangiocarcinoma is not al-
ways accessible despite indications from imaging studies
and clinical condition [7–10]. Surgical resection is the
current therapy of choice for every type of cholangiocar-
cinoma [8, 11, 12]. Resection offers the best opportunity
for long-term survival. Nevertheless, in the minority of
patients and in those with large node-positive or multi-
focal intrahepatic cholangiocarcinoma, resection seems
to provide little benefit [10, 12]. Overall, the 5-year sur-
vival in cholangiocarcinoma cases is poor, with 60 % to
>90 % recurrence rates [7, 9, 13].
Cholangiocarcinoma is relatively rare in most western
countries, but high incidence rates have been reported
in Eastern Asia, especially in Thailand [5, 14–16]. The
etiology of this cancer appears to be mostly due to spe-
cific infectious agents [17, 18]. In 2009, infections with
liver flukes, Clonorchis sinensis or Opisthorchis viverrini,
were both classified as carcinogenic to humans by the
International Agency for Research on Cancer for cholan-
giocarcinoma [14, 18]. With the current systematic
tumor registration in Thailand, new high-incidence areas
have been identified in North and Northeastern
Thailand [10, 17, 19]. Ban Luang is a district in the west-
ern part of Nan Province in Northern Thailand and is
divided into 4 sub-districts. Based on a previous study,
the incidence of liver cancer in Ban Luang was 138.8 per
100,000 persons, which is higher than that of other re-
gions of the world or even in Khon Kaen Province,
which is previously reported as an endemic area for
cholangiocarcinoma [17, 20, 21].
The present study aimed to ascertain the preva-
lence and incidence of cholangiocarcinoma, to iden-
tify predisposing factors, and to explore whether
screening could lead to early treatment and reduction
of morbidity and mortality rates of cholangiocarci-
noma patients.
Methods
Study design and population
A population-based, prospective cohort study for chol-
angiocarcinoma screening included liver ultrasonog-
raphy, stool examination for parasites, complete blood
count (CBC), liver function tests (LFT) including alka-
line phosphatase (ALP), and measurements of hepatitis
B surfaceantigen, hepatitis B core antibody, and serum
carcinoembryonic antigen (CEA), carbohydrate antigen
(CA)19-9, and α-fetoprotein (AFP) every 6 months from
October 2011 to September 2016. This study was ap-
proved by the Ethics Committee for Human Research of
Chulabhorn Research Institute, Bangkok, Thailand
(Certificate no. 29/2554). Written informed consents
were obtained from all the study participants.
Targeted subjects were all indigenous residents of Ban
Luang District, aged 30–60 years, who were not preg-
nant, or breast feeding, or diagnosed with or under
treatment for any type of cancer. Of 6,327 targeted sub-
jects based on a district census registration, 4,337 con-
sented to the study and were recruited by village health
volunteers with the cooperation of Ban Luang Hospital.
Natural history and prevalence and incidence rates of
cholangiocarcinoma were investigated, along with an
analysis of associated risk factors and a comparison of
results between liver ultrasonography and laboratory
testing. People with liver lesions suspected of liver can-
cer, such as isolated mass lesions, masses associated with
bile duct dilatation, or isolated bile duct dilatation with-
out mass lesions were referred for further imaging stud-
ies, including computed tomography (CT), magnetic
resonance imaging (MRI) or magnetic resonance cholan-
giopancreatography (MRCP) at Chulabhorn Hospital. All
cholangiocarcinoma treatments, that is, surgery, chemo-
therapy or radiotherapy, were performed at Chulabhorn
Hospital.
Laboratory and ultrasonography studies
LFT and tumor markers were performed by Cobas 6000
(c501 and e601) of Roche Diagnostics (Thailand) and
liver ultrasonography was performed using Logiq C2
ultrasound system (GE Healthcare) and Aplio 300 and
500 ultrasound system (Toshiba). Recommended diag-
nostic cut-off value for CA19-9, CEA and alkaline phos-
phatase (ALP) was >37 U/mL, ≥4.7 ng/mL, and >100 IU,
respectively. Liver ultrasonography was performed by a
team of radiologists from Chulabhorn Hospital and Nan
Hospital. Criteria for further CT, MRI, and/or MRCP in-
vestigations included nodule/mass lesion, nodule/mass
with bile duct dilatation, and focal bile duct dilatation.
In case of diffuse bile duct dilatation without other asso-
ciated abnormality, MRCP was performed to exclude
small biliary intraductal lesions by using a peripheral bile
duct diameter of ≥ 3 mm. Patients who were diagnosed
as having suspicious/definite malignant lesions by CT,
MRI, and MRCP were subsequently reviewed by a multi-
disciplinary team for further treatment planning. All
cancer specimens were pathologically diagnosed at
Chulabhorn Hospital with routine hematoxylin and
eosin (H&E) staining and immunohistochemistry was
additionally performed if necessary.
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Statistical analysis
Demographic data were reported as mean and standard
deviations for all continuous variables and as propor-
tions and absolute counts for discrete variables. The
Mann-Whitney U test was used to compare continuous
variables, whereas Pearson χ2 and Fisher’s exact tests
were used to compare discrete variables. A two-tailed P
< 0.05 was considered to be significant to verify the as-
sumptions for all statistical tests. Prevalence was calcu-
lated from cholangiocarcinoma patients detected by
initial screening ultrasonography. Incidence was calcu-
lated from new cases detected by subsequent ultrasono-
graphic studies. Disease-free survival (DFS) was defined
as the length of time that the patient survived without
any signs or symptoms, after primary treatment for chol-
angiocarcinoma was completed. Progression-free sur-
vival (PFS) was the length of time during and after
treatment of cholangiocarcinoma that the patients lived
with the disease, without deterioration or progression.
Overall survival (OS) was the length of time that the pa-
tients were still alive, starting from the date of diagnosis
or start of cholangiocarcinoma treatment.
Results
Demographic data of the cohort and prevalence and
incidence of cholangiocarcinoma
Between October 2011 and April 2014, abdominal ultra-
sonography was completed in 4,225 participants (1,919
males and 2,306 females) from 4,337 recruited partici-
pants. Cholangiocarcinoma was detected in 32 patients,
with a mean age of 51.9 years (41–62 years), comprising
18 men (56.3 %) and 14 women (43.7 %). Tables 1 and 2
shows a comparison between cholangiocarcinoma pa-
tients and non-cholangiocarcinoma population. There
was no significant difference between cholangiocarci-
noma patients and non-cholangiocarcinoma population
regarding gender, smoking, history of parasitic infection
and treatment, and raw freshwater animal consumption
(P > 0.05). The mean age of cholangiocarcinoma patients
was 51.9 years and that of non-cholangiocarcinoma
cases was significantly lower at 45.7 years and alcohol
consumption was significantly different between the 2
groups. History of unclassified liver cancer or cholangio-
carcinoma in first-degree relatives was significantly
higher in cholangiocarcinoma patients (33.3 %) than in
the non-cholangiocarcinoma group (17.1 %).
Initial screening revealed 7 asymptomatic cases of
cholangiocarcinoma among 4,225 participants. The
prevalence rate of cholangiocarcinoma in the Ban Luang
population aged 30–60 years was 165.7 per 100,000. We
subsequently detected 6, 4, 5, 7 and 3 cholangiocarcino-
mas from each 6-month follow-up period. The 1- and 2-
year incidence rates were 236.7/100,000 (10/4,225) and
520.7/100,000(22/4,225), respectively.
Ultrasound findings, stages and resectability of
cholangiocarcinoma patients
Of 32 cholangiocarcinoma patients, 10 showed masses
associated with bile duct dilatation, 9 showed isolated
mass lesions, 11 showed isolated bile duct dilatation,
and the other 2 cases showed questionable liver masses
with ultrasonography. Twenty-one cases were resectable
and 11 unresectable. The most common type of cholan-
giocarcinoma was intrahepatic (21/32, 65.6 %). Hilar
type was found in 6 cases (18.8 %) and extrahepatic type
in 5 cases (15.6 %). Based on AJCC Cancer Staging Man-
ual, Seventh edition (2010) [22], there were 5, 10, 2, 2, 8
and 5 patients in stage I, II, IIIa, IIIb, IVa and IVb chol-
angiocarcinoma, respectively. In all stage I patients, re-
sections were performed. In stage II disease, 9 patients
were resected and 1 patient was medically inoperable. In
stage IIIa, one patient was resected and the other was
unresectable. Similarly, in stage IIIb, one patient was
resected and the other was unresectable. In stage IVa, 5
patients had lymph node metastasis but still resectable
lesions and 3 patients were unresectable. All patients in
stage IVb were unresectable due to M1 disease. Add-
itionally, we found 11 patients with premalignant lesions
(or stage 0) (Table 3). With regards to false positive
ultrasonography, we had 3 cases whose surgical speci-
men revealed no malignancy despite suspicious CT and
MRI results. The pathological reports were chronic chol-
angitis with cirrhosis, adenoma with periductal fibrosis
and calcified fibrotic cyst.
Survival rates of patients with cholangiocarcinoma and
premalignant lesions
Over a follow-up period, 1- and 2-year survival rates
were 90.9 and 61.5 %, respectively, for CCA cases
(Table 4). In resectable cases, 1- and 2-year survival rates
were 100 % (16/16) and 77.8 % (7/9). One- and two-year
survival rates were lower in unresectable cases; 66.7 %
(4/6) and 25 % (1/4), respectively. In resectable cases, 1-
and 2-year DFS and recurrent free survival rates were
75 % (12/16) and 44.4 % (4/9), respectively. All patients
with premalignant lesions had excellent outcomes after
surgery (100 % OS and 100 % 2-year DFS).
Values of LFT, tumor markers and stool examination for
parasites
Serum biomarkers, CA19-9, CEA or ALP were analyzed
among cases with and without cholangiocarcinoma as
shown in Table 5. Sensitivity of CA19-9, CEA and ALP
were 18.75, 34.38 and 50.00 %, respectively. When these
tumor makers were combined, the sensitivity was still
low (68.75 %). Stool examination was performed in
3,663 individuals (86.67 %). There were 7 types of para-
sites in 824 cases (22.50 %). O. viverrini-like eggs were
found in 710 cases (19.38 %), Taenia eggs in 56 cases
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(6.17 %), Sarcocystis spp. eggs in 41 cases (4.42 %),
Strongyloides stercoralis eggs in 17 cases (1.85 %), hook-
worm eggs in 45 cases (1.23 %), Trichuris trichiura eggs
in 5 cases (0.14 %), and Enterobius vermicularis eggs in
2 cases (0.05 %). In 22 of 32 cholagiocarcinoma patients,
stool samples were positive for Opisthorchis viverrini,
based on polymerase chain reaction.
Discussion
Cholangiocarcinoma is a silent malignancy with a signifi-
cantly high morbidity and mortality. Patients usually
present at a late stage, rendering curative measures im-
possible to be performed to prolong lives [9, 13]. Al-
though the annual incidence rate of cholangiocarcinoma
in the western countries is low at 1–2 cases per 100,000,
Table 1 Demographic data of cholangiocarcinoma patients and non-cholangiocarcinoma population
Demographic data Total Cholangiocarcinoma
patients (n = 32)
Non- cholangiocarcinoma
population (n = 4,193)
P value
Gender 4,225 32 4,193 0.334a
Male 1,919 18 1,901
(45.4) (56.3) (45.3)
Female 2,306 14 2,292
(54.6) (43.7) (54.7)
Age (year) 45.71 51.91 45.68 <0.001c
History of smoking 4,217 27 4,190 0.092a
Never 2,756 14 2,742
(65.4) (51.9) (65.4)
Ex-smoker 718 9 709
(17.0) (33.3) (16.9)
Active smoker 743 4 739
(17.6) (14.8) (17.7)
Alcoholic consumption 4,217 27 4,190 <0.001b
Never 1,315 9 1,306
(31.2) (33.4) (31.2)
Ex-consumption 492 10 482
(11.7) (37.0) (11.5)
Light consumption (< once a month) 1,360 4 1,356
(32.2) (14.8) (32.3)
Moderate to heavy consumption 1,050 4 1,046
(24.9) (14.8) (25.0)
Any liver cancers or cholangiocarcinoma in first-degree relatives 4,202 27 4,175 0.037a
Yes 722 9 713
(17.2) (33.3) (17.1)
No 3,480 18 3,462
(82.8) (66.7) (82.9)
Diagnosis of liver fluke 4,153 27 4,126 0.366a
Ever 753 7 746
(18.1) (25.9) (18.1)
Never 3,293 19 3,274
(79.3) (70.4) (79.3)
Unknown 107 1 106
(2.6) (3.7) (2.6)
a Fisher’s exact test
b Pearson’s χ2 test
c Mann–Whitney U test
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many studies have documented a steady increase in the
incidence of intrahepatic cholangiocarcinoma over the
past few decades; increases have been seen in North
America, Europe, Asia, and Australia [2, 4, 6]. Our study
confirmed a high prevalence and high incidence rate of
cholangiocarcinoma in Thailand, particularly in the
northern region of the country with a prevalence rate of
165.7 per 100,000 and 1- and 2-year incidence rates of
236.7/100,000 and 520.7/100,000, respectively [10, 17].
As a screening program for cholangiocarcinoma is cur-
rently not established worldwide, this study was
intended to explore if abdominal ultrasonography or
tumor markers could be of benefit to detect early-stage
cases for curative intent in an endemic area. By perform-
ing successive ultrasonography every 6 months, we man-
aged to identify 32 cholangiocarcinoma cases from 1 to
6 sessions over a 3-year period and 65 % of our patients
were diagnosed with early-stage and operable tumors
which was markedly different from all the hospital-based
data previously reported in Thailand whereby most chol-
angiocarcinoma cases presented at a late stage. A recent
study from the National Cancer Institute of Thailand
showed that there were 2.17, 12.69, 24.77, and 57.89 %,
respectively, of stage I, II, III, and IV of newly diagnosed
cholangiocarcinoma cases diagnosed at their institute in
2013 [23]. Nevertheless, the most common tumor loca-
tion in this study was intrahepatic which was similar to
other published hospital-based studies [7, 12, 24].
Over a follow-up period of 3 years, 1- and 2-year sur-
vival rates of the affected cases were high (>60 %), par-
ticularly in resectable cases (100 and 78 %, respectively)
as expected, and were much better than those reported
from previous studies in Thailand and Malaysia with ad-
vanced and inoperable cases [10, 11, 25]. Outcome data
from a study in Khon Kaen of 411 intrahepatic cholan-
giocarcinoma patients revealed that only 138 cases were
resectable and the mean survival time was 1,039 days
in tumor stage III, 773 days in stage IVa, and 382 days
in stage IVb [10]. Rare long-term survival with a one-
year survival of just 15 % was reported in perihilar
Table 3 Pathological data of patients with premalignant lesions
No. Sex Age Pathology
1 M 45 Intraductal cholangiocarcinoma
2 M 60 Intraductal papillary biliary neoplasm
3 F 53 Biliary epithelial neoplasm
4 F 51 Low grade dysplastic epithelium
5 F 52 Intraductal papillary biliary neoplasm
6 M 41 High grade dysplastic epithelium
7 F 59 Hyperplasia + dysplastic epithelium
8 F 59 Intraductal papillary biliary neoplasm
9 F 53 Atypical bile duct epithelium
10 F 56 Intraductal papillary biliary neoplasm
11 M 51 Intraductal papillary biliary neoplasm






1-year 2-year 1-year 2-year 1-year 2-year
OS 100 % 100 % 75 % 44.4 % 33.3 % 0 %
DFS/PFS 100 % 100 % 100 % 77.8 % 66.7 % 25 %
Abbreviations: OS overall survival, PFS progression free survival, DFS disease
free survival
Table 2 Demographic data of cholangiocarcinoma patients and non-cholangiocarcinoma population





Any treatment for liver flukes from physicians/public
health personnel
4,129 27 4,102 0.233b
Ever 1,441 7 1,434
(34.9) (25.9) (35.0)
Never 2,576 18 2,558
(62.4) (66.7) (62.3)
Unknown 112 2 110
(2.7) (7.4) (2.7)
Raw freshwater fish/shrimp/snail consumption 4,218 27 4,191 0.568a
Yes 526 2 524
(12.5) (7.4) (12.5)
No 3,692 25 3,667
(87.5) (92.6) (87.5)
a Fisher’s exact test
b Pearson’s χ2 test
c Mann-Whitney U test
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cholangiocarcinoma cases [11]. Another long term
follow-up data from Malaysia in 69 cholangiocarci-
noma patients showed that the overall median sur-
vival was 4 months with the median survival of
16 months in R0 resected patients [25]. Overall 1-, 2-
and 3-year survival rates were 67, 17 and 17 %, re-
spectively. In one study from the US, 53.8 % of newly
diagnosed intrahepatic cholangiocarcinoma patients
were not candidates for resection [12]. In resectable
groups, the median disease-specific survival was
36 months and recurrence was observed in most of
the patients (62.2 %). In unresectable groups, the me-
dian survival varied depending on modalities of treat-
ments, i.e., 22 months and 9 months in patients
receiving regional chemotherapy as part of treatment
and systemic chemotherapy alone, respectively. Al-
though our outcomes could not be directly compared
because other reports were from hospital-based stud-
ies, it is evident that screening ultrasonography could
identify patients at an early and asymptomatic stage
leading to better treatment outcomes.
Interestingly, our study identified 11 patients with pre-
malignant lesions (stage 0) such as biliary intraepithelial
neoplasia, intraductal papillary biliary neoplasm or dys-
plastic epithelium [26]. Our pathological results were
achievable because we detected patients at the earliest
stage whereas most studies of cholangiocarcinoma did
not have pathological tissue due to the inoperative na-
ture of the late-stage cases. These premalignant lesions
represent cases whereby abnormal cells were found in
the innermost layer of the tissue lining of the extrahe-
patic bile duct. All of them did better than the early-
stage cholangiocarcinoma cases with 100 % DFS and are
still alive at 3-year follow-ups. Therefore, patients detected
at a premalignant stage appeared to benefit the most from
screening ultrasonography and potentially are cured.
With regards to demographic data, the population in
Ban Luang is socioeconomically comparable to rural
northern and northeastern population of Thailand with
similar ethnic backgrounds [27]. The villagers’ major oc-
cupation was farming with an average income per
month of 1,000–4,999 THB (about 30–145 USD). The
mean age of cholangiocarcinoma cases of 51.9 years old
in this study was consistent with the average age of
cholangiocarcinoma cases reported from the National
Cancer Registry or hospital-based studies [28] but was
much lower than most western data whereby most pa-
tients are in their 60s or 70s [2, 4, 13]. During our 3-year
study period, no cancer patients under the age of 40 years
old were identified. Hence, age could be another factor in
disease development and cholangiocarcinoma screening
in individuals younger than 40 years old may not be of
value or necessary in an endemic area. Similar to some
previous data, the prevalence of cholangiocarcinoma was
slightly higher in males as compared to females [29, 30].
Other significant demographic data was a history of alco-
hol drinking and a family history of liver cancer in the
cholangiocarcinoma cases as compared to non-cancer co-
hort, which could be important for the development of
cholangiocarcinoma. In addition, we found a strong family
history of cholangiocarcinoma in some patients. Cholan-
giocarcinoma patients had many first-degree relatives with
liver cancer although most of them were diagnosed
only by clinical suspicion, for example, obstructive
jaundice with abdominal mass, mostly without histo-
logical confirmation.
Table 5 Tumor marker analysis in the cases with and without cholangiocarcinoma
Predictor Cholangiocarcinoma Total Sensitivity Specificity PPV NPV
Positive Negative
Positive CA19-9 6 59 65 18.75 98.63 9.23 99.39
Negative CA19-9 26 4245 4271
Total 32 4304 4336
Positive CEA 11 749 760 34.38 82.60 1.45 99.41
Negative CEA 21 3555 3576
Total 32 4304 4336
Positive ALP 15 641 656 50.00 83.54 2.29 99.54
Negative ALP 15 3254 3269
Total 30 3895 3925
Positive CA19-9 or CEA or ALP 22 1252 1274 68.75 70.91 1.73 99.67
Negative CA19-9 or CEA or ALP 10 3052 3062
Total 32 4304 4336
Abbreviations: CA19-9 carbohydrate antigen 19–9, CEA carcinoembryonic antigen, ALP alkaline phosphatase, NPV negative predictive value, PPV positive
predictive value
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Although risk factors for the development of cholangio-
carcinoma in the western countries are primary sclerosing
cholangitis, an inflammatory disease of the biliary tract,
and ulcerative colitis, certain parasitic liver diseases are
notable risk factors in Asia. Colonization with the liver
flukes O. viverrini (in Thailand, Laos and Vietnam) [31–
33] or Clonorchis sinensis (in China, Taiwan, Eastern
Russia, Korea, and Vietnam) is associated with the devel-
opment of cholangiocarcinoma [34]. In this study, we
found that about 18–25 % of our villagers had a history of
liver flukes and 25–35 % of them had been treated with
drugs to eradicate the parasites but no significant differ-
ence was observed between the cancer cases and the non-
cancer cases. There are many potential problems with de-
tecting O. viverrini eggs by microscopic examination. For
example, the egg features are similar to those of lecitho-
dendrid and heterophyid parasites, therefore, the examin-
ation requires a high level of skill, and the methods are
time consuming. To overcome these constraints, with the
cooperation of the Department of Helminthology, Faculty
of Tropical Medicine, Mahidol University, stool internal
transcribed spacer (ITS)-PCR, which is a more sensitive
and specific method, was performed in 22 cholangiocarci-
noma patients during the first 2 years of the study [35].
All patients had positive results from stool PCR for O.
viverrini, suggesting that O. viverrini continues to be an
important contribution factor to the development of chol-
angiocarcinoma in Thailand.
Although we could detect early-stage disease and the
majority of patients were able to receive curative surgery,
the recurrence rate was still not as low as expected, neces-
sitating our attempts to identify if tumor markers could be
of better benefit than ultrasonography for early screening.
Our study confirmed that currently available tumor
markers have inadequate sensitivity and specificity for
cholangiocarcinoma screening [36, 37]. These markers,
such as CEA, CA 19–9, ALP, were not sensitive enough to
detect early cholangiocarcinoma cases in our study cohort.
Other new biological markers may be needed to identify
patients at the earliest stage that will potentially lead to
curative success [35, 38, 39]. Nevertheless, with the excel-
lent outcome of our patients with premalignant lesions,
we suggest that ultrasonography should be a first screen-
ing tool for cholangiocarcinomain an endemic area until
other useful biological markers are discovered or become
available. Studies are ongoing to identify new genomic
and proteomic markers for cholangiocarcinoma cases in
Thailand [40]. New therapeutic advances are also needed
to improve the disease-free survival of patients undergoing
surgical resection [41, 42].
Conclusions
This study represents the first large population-based
screening program ever performed in an endemic area
of cholangiocarcinoma by serial ultrasonography coupled
with laboratory tests. The high prevalence and incidence
rates of cholangiocarcinoma in Northern Thailand were
evident. Current tumor markers and stool examination
for parasites are not of benefit for cholangiocarcinoma
screening in an endemic area. Ultrasonography should
be offered as a first screening tool for cholangiocarci-
noma in individuals aged ≥40 in an endemic area. Pa-
tients with premalignant lesions achieved the most
benefit from screening ultrasonography and are poten-
tially cured. Future studies are needed to identify new
biological markers that will capture cancer cells at the
earliest stage of development.
Abbreviations
AFP, α-fetoprotein; ALP, alkaline phosphatase; CA 19–9, carbohydrate antigen
19–9; CBC, complete blood count; CCA, cholangiocarcinoma; CEA, carci-
noembryonic antigen; CT, computed tomography; DFS, disease-free survival;
H&E, hematoxylin and eosin; ITS, internal transcribed spacer; IU, international
unit; LFT, liver function tests; mL, millilitre; mm, millimeter; MRCP, magnetic
resonance cholangiopancreatography; MRI, magnetic resonance imaging; ng,
nanogram; NPV, negative predictive value; O. viverrini, Opisthorchis viverrini; OS,
overall survival; PCR, polymerase chain reaction; PFS, progression-free survival;
PPV, positive predictive value; U, unit.
Acknowledgments
We appreciated all individuals, particularly the people of Nan Province, the staff
of Chulabhorn Hospital, Nan Hospital and Ban Luang Hospital, including
doctors, nurses, coordinators, the Nursing Division, and the Data Management
team who generously spared their time for the accomplishment and fulfillment
of this project. The excellent parasitic investigations by Faculty of Tropical
Medicine, Mahidol University is also acknowledged.
Funding
The project is funded by Chulabhorn Hospital Research Grant (Certificate no.
29/2554).
Availability of data and materials
We do not wish to share all the data at the present time as the project is still
ongoing. The full data set should be available by early spring of 2017 when
the whole project is completed.
Authors’ contributions
PS performed data collection, data analysis and manuscript drafting. SS, SV,
AW and SS performed ultrasonography and imaging analysis. KA was
responsible for subject recruitment, project coordination, and follow-ups of
the cohort. TS reviewed and reported pathological results. RS and CB
performed hepatic surgeries for the patients. SS and RM helped coordinating
the appointments and follow-ups of the participants and patients. MY and
GS were responsible for biospecimen collection and laboratory studies. KW
and KS performed data management and statistical analysis. CA reviewed
the study design, monitored the project, and critically revised the final
manuscript. CM was responsible for the initiation and execution of the entire
project. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was approved by the Ethics Committee for Human Research of
Chulabhorn Research Institute, Bangkok, Thailand (Certificate no. 29/2554).
Written informed consents were obtained from all the study participants
using the Ethics Committee’ approved forms.
Sungkasubun et al. BMC Cancer  (2016) 16:346 Page 7 of 8
Author details
1Chulabhorn Hospital, 54 Kamphaeng Phet 6 Road, Laksi, Bangkok 10210,,
Thailand. 2Ban Luang Hospital, 191 Pa Kha Luang, Ban Luang, Nan 55190,
Thailand. 3Faculty of Medicine Siriraj Hospital, Mahidol University, 2
Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand. 4National Cancer
Institute of Thailand, 268/1 Rama VI Road, Ratchathewi, Bangkok 10400,
Thailand. 5Chulabhorn Research Institute, 54 Kamphaeng Phet 6 Road, Laksi,
Bangkok 10210, Thailand.
Received: 23 December 2015 Accepted: 26 May 2016
References
1. Ustundag Y, Bayraktar Y. Cholangiocarcinoma: a compact review of the
literature. World J Gastroenterol. 2008;14(42):6458–66.
2. Patel T. Increasing incidence and mortality of primary intrahepatic
cholangiocarcinoma in the United States. Hepatology. 2001;33(6):1353–7.
3. West J, Wood H, Logan RF, Quinn M, Aithal GP. Trends in the incidence of
primary liver and biliary tract cancers in England and Wales 1971–2001. Br J
Cancer. 2006;94(11):1751–8.
4. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC.
Changing international trends in mortality rates for liver, biliary and
pancreatic tumours. J Hepatol. 2002;37(6):806–13.
5. Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM. Impact of
classification of hilar cholangiocarcinomas (Klatskin tumors) on the
incidence of intra- and extrahepatic cholangiocarcinoma in the United
States. J Natl Cancer Inst. 2006;98(12):873–5.
6. McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the
incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in
the United States. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1198–203.
7. Malhi H, Gores GJ. Cholangiocarcinoma: Modern advances in understanding
a deadly old disease. J Hepatol. 2006;45(6):856–67.
8. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis. 2008;12(1):131–50. ix.
9. Thunyaharn N, Promthet S, Wiangnon S, Suwanrungruang K, Kamsa-ard S.
Survival of cholangiocarcinoma patients in northeastern Thailand after
supportive treatment. Asian Pac J Cancer Prev. 2013;14(11):7029–32.
10. Uttaravichien T, Bhudhisawasdi V, Pairojkul C, Pugkhem A. Intrahepatic
cholangiocarcinoma in Thailand. J Hepatobiliary Pancreat Surg. 1999;6(2):
128–35.
11. Khuntikeo N, Pugkhem A, Titapun A, Bhudhisawasdi V. Surgical
management of perihilar cholangiocarcinoma: a Khon Kaen experience. J
Hepatobiliary Pancreat Sci. 2014;21(8):521–4.
12. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic
cholangiocarcinoma: rising frequency, improved survival, and determinants
of outcome after resection. Ann Surg. 2008;248(1):84–96.
13. Mihalache F, Tantau M, Diaconu B, Acalovschi M. Survival and quality of life
of cholangiocarcinoma patients: a prospective study over a 4 year period. J
Gastrointestin Liver Dis. 2010;19(3):285–90.
14. Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, et al.
Epidemiology of cholangiocarcinoma: an update focusing on risk factors.
Cancer Sci. 2010;101(3):579–85.
15. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence,
mortality, and prevalence across five continents: defining priorities to
reduce cancer disparities in different geographic regions of the world. J Clin
Oncol. 2006;24(14):2137–50.
16. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer
statistics. CA Cancer J Clin. 2011;61(2):69–90.
17. Vatanasapt V, Martin N, Sriplung H. Cancer in Thailand 1988–1991 (No. 16).
Bangkok: IARC Technical Report; 1993. p. 88–9.
18. Brindley PJ, da Costa JM, Sripa B. Why does infection with some helminths
cause cancer? Trends Cancer. 2015;1(3):174–82.
19. Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. Curr Opin
Gastroenterol. 2008;24(3):349–56.
20. Siriarayapon P, Taprasert P, Kongyu S. Epidemiology of Liver Cancer in
Banluang District, Nan Province. Weekly Epidemiol Surveillance Rep. 2006;37(3s).
21. Hakulinen T. Cancer Incidence in Five Continents. Vol. VII. Parkin DM,
Whelan SL, Ferlay J, Raymond L and Young J. ed. IARC Scientific
Publications No. 143, Lyon; 1997.
22. Egner JR. AJCC Cancer Staging Manual. JAMA. 304(15):1726-1727.
23. Hospital-Based Cancer Registry. National Cancer Institute. 2013. http://www.
nci.go.th/th/File_download/Nci%20Cancer%20Registry/HOSPITAL-
BASED%202013%20All%20(Online)%20(1).pdf. Accessed 20 Mar 2016.
24. Maithel SK, Gamblin TC, Kamel I, Corona‐Villalobos CP, Thomas M, Pawlik
TM. Multidisciplinary approaches to intrahepatic cholangiocarcinoma.
Cancer. 2013;119(22):3929–42.
25. Yusoff AR, Razak MM, Yoong BK, Vijeyasingam R, Siti ZM. Survival analysis of
cholangiocarcinoma: a 10-year experience in Malaysia. World J
Gastroenterol. 2012;18(5):458–65.
26. Nitta T, Nakanuma Y, Sato Y, Hirano S, Pairojkul C. Pathological
characteristics of intraductal polypoid neoplasms of bile ducts in Thailand.
Int J Clin Exp Pathol. 2015;8(7):8284–90.
27. Per Capita Income of Population by Region and Province: 1995–2013. Office
of the National Economic and Social Development Board, Office of the
Prime Minister. www.nesdb.go.th/. Accessed 25 Mar 2016.
28. Suzuki H, Isaji S, Pairojkul C, Uttaravichien T. Comparative clinicopathological
study of resected intrahepatic cholangiocarcinoma in northeast Thailand
and Japan. J Hepatobiliary Pancreat Surg. 2000;7(2):206–11.
29. Chang JS, Tsai CR, Chen LT. Medical risk factors associated with
cholangiocarcinoma in Taiwan: a population-based case–control study.
PLoS One. 2013;8(7), e69981.
30. Singal AK, Vauthey JN, Grady JJ, Stroehlein JR. Intra-hepatic
cholangiocarcinoma–frequency and demographic patterns: thirty-year data
from the M.D. Anderson Cancer Center. J Cancer Res Clin Oncol. 2011;
137(7):1071–8.
31. Sripa B, Kaewkes S, Sithithaworn P, Mairiang E, Laha T, Smout M, et al. Liver
fluke induces cholangiocarcinoma. PLoS Med. 2007;4(7), e201.
32. Watanapa P, Watanapa WB. Liver fluke-associated cholangiocarcinoma. Br J
Surg. 2002;89(8):962–70.
33. Young ND, Nagarajan N, Lin SJ, Korhonen PK, Jex AR, Hall RS, et al. The
Opisthorchis viverrini genome provides insights into life in the bile duct.
Nat Commun. 2014;5:4378.
34. Hong ST, Fang Y. Clonorchis sinensis and clonorchiasis, an update. Parasitol
Int. 2012;61(1):17–24.
35. Sato M, Pongvongsa T, Sanguankiat S, Yoonuan T, Dekumyoy P,
Kalambaheti T, et al. Copro-DNA diagnosis of Opisthorchis viverrini and
Haplorchis taichui infection in an endemic area of Lao PDR. Southeast Asian
J Trop Med Public Health. 2010;41(1):28.
36. Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H, Haglund C.
CEA, CA 19–9 and CA 72–4 improve the diagnostic accuracy in
gastrointestinal cancers. Anticancer Res. 2001;22(4):2311–6.
37. Pungpak S, Akai P, Longenecker B, Ho M, Befus A, Bunnag D. Tumour
markers in the detection of opisthorchiasis-associated cholangiocarcinoma.
Trans R Soc Trop Med Hyg. 1991;85(2):277–9.
38. Yongvanit P, Pinlaor S, Loilome W. Risk biomarkers for assessment and
chemoprevention of liver fluke-associated cholangiocarcinoma. J
Hepatobiliary Pancreat Sci. 2014;21(5):309–15.
39. Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, et al.
Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet.
2012;44(6):690–3.
40. Chaisaingmongkol J, Budhu A, Dang H, Rabibhadana S, Pupacdi B, Forgues
M, et al. Abstract LB-173: The Thailand initiative in genomics and expression
research for liver cancer (TIGER-LC): Defining novel subtypes of
hepatocellular carcinoma and cholangiocarcinoma. Cancer Res. 2015;75(15
Supplement):LB-173.
41. Kabbach G, Assi HA, Bolotin G, Schuster M, Lee HJ, Tadros M. Hepatobiliary
tumors: update on diagnosis and management. J Clin Transl Hepatol. 2015;
3(3):169–81.
42. Rizvi S, Borad MJ, Patel T, Gores GJ. Cholangiocarcinoma: molecular
pathways and therapeutic opportunities. Semin Liver Dis. 2014;34(4):456–64.
Sungkasubun et al. BMC Cancer  (2016) 16:346 Page 8 of 8
